What is the significance of this filing being an '10-K/A'?

An '10-K/A' signifies an amendment to a previously filed 10-K annual report. This means Merck & Co., Inc. is providing updated, corrected, or additional information related to its 1995 fiscal year after the initial filing. Investors should pay close attention to the nature of these amendments as they may contain material information.

What period does this filing cover?

This amendment pertains to Merck & Co., Inc.'s fiscal year that ended on December 30, 1995.

Where can I find the actual financial statements and management discussion within this filing?

The provided text is a directory listing of the filing's contents on the SEC's EDGAR system. To access the financial statements, Management's Discussion and Analysis (MD&A), and other detailed sections, you would need to navigate to the specific .txt or .html files linked within the full EDGAR database, such as the '-96-000011.txt' file.

What should investors look for in this amendment?

Investors should look for any changes or elaborations made to the original 10-K filing, particularly concerning financial results, accounting policies, significant events during 1995, risk factors, and any legal or regulatory disclosures. It's important to compare the amended content with the original filing to understand the impact of any revisions.

MRK 10-K Filed Jun 25, 1996

Summary

This filing represents an amendment to Merck & Co., Inc.'s 1995 Annual Report on Form 10-K, filed on June 24, 1996. As an amendment, it likely addresses previously filed information or provides updated details for the fiscal year ending December 30, 1995. Investors should note that this filing follows the initial report and may contain corrections or additional disclosures crucial for a complete understanding of the company's financial position and performance during that period. Key areas to scrutinize in such amendments typically include financial statement adjustments, management's discussion and analysis (MD&A) clarifications, or updates on legal or regulatory matters that arose post-initial filing. For investors, understanding the nature of the amendment is paramount to assess any potential impact on previously reported earnings, assets, liabilities, or future outlook. It is essential to compare the amended information against the original filing to identify the specific changes and their implications.

Key Highlights

1Amendment to the 1995 10-K Filing: This document is an amendment (10-K/A) to the original 10-K filing for Merck & Co., Inc. for the fiscal year ending December 30, 1995.
2Filing Date: The amendment was filed on June 24, 1996, indicating updates or corrections to information previously submitted.
3Focus on Financial Performance and Disclosures: Investors should review this amendment to understand any revised financial data, management commentary, or disclosures that might impact the company's reported performance for 1995.
4Potential for Material Changes: Amendments can sometimes signal material changes to previously reported figures or strategic information that are important for investment decisions.
5Importance of Cross-Referencing: It is crucial for investors to compare the information in this amendment against the original 10-K filing to identify specific changes and their significance.
6Regulatory Compliance and Transparency: Such amendments highlight Merck's commitment to regulatory compliance and transparent financial reporting to the SEC.

Merck & Co., Inc. Annual Report (Amendment), Year Ended Dec 31, 1995

Summary

Key Highlights

Frequently Asked Questions